Lybrel, Torisel launches underway
Executive Summary
Wyeth is shipping its May approvals in earnest beginning this month, firm says during a July 19 earnings call. Launches of continuous oral contraceptive Lybrel (levonorgestrel/ethinyl estradiol) and renal cell carcinoma treatment Torisel (temsirolimus) are the first of seven launches planned for the next 18 months, Chief Operating Officer Bernard Poussot says. Promotional materials are being finalized and active promotion will begin shortly, Poussot adds (1"The Pink Sheet" June 4, 2007, p. 3)...